All In Biotech

Drug Trial Radar · NCT04795037

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CU06-1004 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Jul 15, 2021

Primary completion

Mar 2, 2022

Study completion Jun 25, 2022

Sponsor

Lead sponsor
Curacle Co., Ltd.Industry
Sponsor type
Industry
Collaborators
KCRN Research, LLC
First posted
Mar 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

Conditions

  • Diabetic Macular Edema

Interventions

  • CU06-1004, Single doseDrug

    Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)* *Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5

  • CU06-1004, Multiple dosesDrug

    Multiple doses of CU06-1004, 7 days, 3 dose levels*, oral capsule *The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD

  • PlaceboDrug

    Placebo matched to CU06-1004, oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs)Time frame: From the date of first dose through 7 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.